Announced Mon, 6 Jul · 17:58 IST
Nephrocare provides USD 3.3 Mn collateral for Singapore subsidiary
General View source PDF
NEPHROPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-4.4%1-day move
₹673.95
prior close
₹679.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.4-1.3-1.9-1.9-4.4-5.6-3.3-4.0-5.0-5.2————
Up moveDown movePending
AI summary
Nephrocare Health Services has provided collateral/security support of USD 3.3 million (about INR 31.22 Crore) to Citibank for its Singapore-based wholly-owned subsidiary NHSI. This enables the subsidiary to raise fund-based and non-fund-based credit facilities. The Board had approved this earlier in May 2026. The move creates a contingent financial exposure for the parent company, but promoters have no direct interest in the deal.
Likely market impact
Creates a contingent exposure of about INR 31.22 Crore for the parent. No immediate cash flow impact, but risk rises if the Singapore subsidiary defaults.